glp 1 agonist history Another milestone in the evolution of GLP-1-based diabetes therapies Albiglutide - an overview |

doi: 10.1186/s12933-020-01211-4

Subramaniam et al

Corley serves as a scientific advisor for TruDiagnostic.

2 This effect may arise from mechanisms involving reduced ectopic fat accumulation and better cellular glucose uptake

For instance, exenatide, the first GLP-1-analogue developed, demonstrated to promote human monocyte differentiation into alternatively activated M2 macrophages, leading to an increase in anti-inflammatory cytokines such as IL-10 while significantly reducing pro-inflammatory cytokines, including IL-6, TNF- and IL-1 ( Furthermore, GLP-1 has been hypothesised to act as a mediator between innate and adaptive immune responses

This idea was bolstered by a series of experiments conducted between 1890 and 1905 by Marcel Eugne mile Gley, a French physiologist